Form 4: Lantern Pharma Director Acquires Stock Options

D. Jeffrey Keyser, a director at Lantern Pharma Inc., acquired 5,000 stock options on July 15, 2024, under the company's 2018 Stock Incentive Plan.

Summary

• On July 15, 2024, D. Jeffrey Keyser, a director of Lantern Pharma Inc., acquired 5,000 stock options.
• The options were granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan.
• The exercise price of the options is $4.35.
• The options vest in equal monthly increments over a 36-month period, starting August 15, 2024.
• The options expire on July 15, 2034.
• Following the transaction, Keyser directly owns 5,000 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document simply reports the grant of stock options to a director, which is a routine event. It doesn't contain any information that would strongly suggest a positive or negative outlook.

Positives

• A director's acquisition of stock options can be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It's common for directors and officers of publicly traded companies to receive stock options as part of their compensation.

Stakeholder Impact

• The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.

Key Dates